Vice President of Clinical Development Richard Mohs, PhD, presented at this international conference on Alzheimer’s drug discovery sponsored by the Alzheimer’s Drug Discovery Foundation.
Join the AgeneBio team at these upcoming industry events.
Vice President of Research and Development Sharon Rosenzweig-Lipson, PhD, presented at this international conference on Alzheimer’s drug discovery sponsored by the Alzheimer’s Drug Discovery Foundation. During the conference, Dr. Rosenzweig-Lipson was interviewed by NJTV News.
CEO Jerry McLaughlin will present at the Neuroscience BioPartnering & Investment Forum on Tuesday, February 23, at 3:35 pm Eastern Time. The BIO CEO & Investor Conference is being held at The New York Academy of Sciences.
CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at 10:15 am Eastern Time. The BIO CEO & Investor Conference is being held February 8 and 9 at the Waldorf Astoria New York.
Future of Innovation in Medicine Conference: Incentives for New Medical Treatments and Global Health
CEO Jerry McLaughlin will participate on a panel entitled, “Access to Medicine: Charities, Academics & Industry Collaboration for New Treatments,” on Thursday, December 3, at 3:45 pm Pacific Time.
CEO Jerry McLaughlin will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” on November 19 in Boston.
Clinical Trial in MCI Reducing Hippocampal Overactivity: HOPE4MCI AgeneBio’s Michela Gallagher and Sharon Rosenzweig-Lipson to present in Barcelona on Saturday, November 7, 2015, at 11:45 am
October 20-21, 2015, San Francisco, CA. CEO Jerry McLaughlin will speak on Wednesday, October 21, at 9 am Pacific time.
AgeneBio’s Michela Gallagher spoke on the impact and role of NIH funding on advances in science and clinical trials targeting the prevention of Alzheimer’s disease on Wednesday, September 30, 2015, in Washington, DC.
January 12 – 14, 2015, San Francisco, CA. CEO Jerry McLaughlin spoke on Tuesday, January 13.